Poland nationalupdate 16th October 2014 Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID)
Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area The survey was conducted by the AIDS Social Committee from the funds granted by the National Bureau for Drug Prevention and the Global Drug Policy Programme in Open Society Foundations. The project was implemented according to cross-sectional design based on anonymous questionnaires containing closed and openended questions as well as HIV and HCV lab tests (screening tests and Western Blot). The survey was conducted between 6 December 2013 and 23 May 2014. Population: ever-injectors, over 18 years of age, residing in Warsaw and the surrounding area during 3 months prior to the study Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS.
Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area Recruitment: the respondents were recruited by trained volunteer leaders active drug users and patients of methadone programmes and through invitations distributed via drug services. Sample: the final sample size was 96 (95 persons were tested) 60 participants were recruited by active drug users the majority were male and at the age of 30-39 Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS.
Numbers of participants by age and gender 60 50 40 30 20 10 0 36 15 15 7 14 5 0 2 20-29 30-39 40-49 >=50 male female Total: 96 Male: 70 Female: 24 Not known: 2 Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS.
HIV, HCV prevalence Estimated HIV prevalence among ever injectors - 14.7%. Estimated HCV prevalence among ever injectors 71.6%. 73.7% study participants were HIV and/or HCV positive. Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS. In 2004 Warsaw(N=200) HIV prevalence 16% HCV prevalence 60% Source: Estimation of infectious diseases prevalence (HCV, HBV, HIV) among PWID National Institute of Hygiene, 2004
Riskybehaviours 64.2% of participants injected drugs during 30 days preceding the study. 94.7% of study participants declared receiving clean equipment for injections. The main sources for the respondents were the pharmacies (87.2% of respondents) and needle, syringe exchange programs (30.9% of respondents). The majority of study participants were informed on the risk of HIV and HCV (respectively 68.1% and 69.1%). Among those who received the information on HIV and/or HCV transmission 73.8% were HIV and/or HCV positive. Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS.
Sterileinjectingequipment 35.7% of HIV-positive users received sterile injecting equipment from the pharmacies while 64.3% declared drop-in points as the source of clean equipment. 89.6% of HCV-positive users received sterile injecting equipment from the pharmacies, 38.8% contacted drop-in points. Source: Report form the study Estimation of HIV and HCV prevalence among injecting drug users in Warsaw and the surrounding area (2014) Społeczny Komitet ds. AIDS.
Commentsto the pilot study The recruitment method seems to be effective, especially involvment of trained volunteer leaders active drug users and patients of methadone programmes, Characteristic of HIV/HCV positive drug user
Number of new HIV infections, including injecting drug use (recorded number and corrected value imputing missing data on route of transmission) detected in 2000-2013 1200 1118 1095 1090 1000 958 955 810 804 840 800 600 633 579 548 702 670 703 All HIV infections IDU - induced HIV infections 400 200 334 300 196 265 212 159 126 99 IDU - corrected value 55 60 43 64 43 38 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Source: National Institute of Public Health National Institute of Hygiene
HIV frequency in diagnostic testing in IDUs in 2007 2013 2007 2008 2009 2010 2011 2012 2013 Number of HIVpositive IDUs 121 101 65 45 26 11 10 Number of all IDUs tested for HIV (valid tests) 1064 1084 1176 657 884 219 217 HIV frequency rate 0.114 0.093 0.055 0.068 0.029 0.0502 0.046 Source: National Institute of Public Health National Institute of Hygiene
Number of consultation and testing sites (PKD) total: 32 Since 1996 a network of consultation and testing sites (PKDs) has been operating in Poland. The sites provide anonymous and free HIV testing combined with preliminary consultation. The PKD network is run by NGOs closely collaborating with drug treatment units and is coordinated and cofinanced by the National AIDS Centre. Source: National AIDS Centre
HIV transmission routes among all PKD clients (percentages of clients) in 2013 Source: National AIDS Centre In 2011 the total number of PKD clients was 29 826 and 369 of them received a positive HIV test result.
Percentage of positive results in IDU population in 2010 (n=333) 8,10% Percentage of positive results in IDU population in 2011(n=224) 14,7% 91,90% HIV+ 85,3% HIV+ HIV- HIV- Percentage of positive results in IDU population in 2012(n=186) 9,1% HIV+ 90,9% HIV- IDUs more frequently test in PKD that are nearby the methadone maintenance programs and outpatient treatment centres. Source: National AIDS Centre
Number of syringe and needle programmes in Poland in 2002-2012 25 20 15 10 5 23 21 21 19 16 16 15 15 15 15 12 12 13 13 11 10 10 8 12 12 9 10 No. of programs No. of cities 0 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 National Report 2013
Numbers of NSPs clients in Poland in 2004-2012 6000 5000 4000 4614 5091 4002 3228 3101 3100 3000 2000 2022 2111 1528 1000 0 2004 2005 2006 2007 2008 2009 2010 2011 2012 National Report 2013
Numbers of OST clients 2000 1800 1600 1583 1725 1400 1200 1271 1000 960 800 600 400 549 694 200 0 2008 2009 2010 2011 2012 2013 Source: National Bureau for Drug Prevention
Furtheranalysis Analysis of TDI data on HIV/HCV testing Analysis of PKD data Sero-behavioural studies Survey among clients of syringes and needles exchange programmes (self-reported data)
Thank you! nfpp@kbpn.gov.pl